Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IDXG

Interpace Biosciences (IDXG) Stock Price, News & Analysis

Interpace Biosciences logo

About Interpace Biosciences Stock (NASDAQ:IDXG)

Advanced Chart

Key Stats

Today's Range
$0.79
$0.85
50-Day Range
$4.75
$10.40
52-Week Range
$2.57
$10.42
Volume
15,600 shs
Average Volume
6,816 shs
Market Capitalization
$3.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXG Stock News Headlines

SPDI Announces Arcona Share Distribution Timetable
PDI: 3 Reasons To Run Far Away As Possible
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
PDI CEF: Best Time To Sell In 5 Years
PDI Declares Monthly Dividend with Over 13% Yield
PDI: Credit Offers Opportunity In An Expensive Market
PDI: Get In Before The Fed Changes The Tune
See More Headlines

IDXG Stock Analysis - Frequently Asked Questions

Interpace Biosciences, Inc. (NASDAQ:IDXG) announced its quarterly earnings results on Monday, November, 4th. The business services provider reported $0.31 earnings per share for the quarter. The business services provider had revenue of $12.30 million for the quarter. Interpace Biosciences had a negative trailing twelve-month return on equity of 8.09% and a net margin of 10.39%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX).

Company Calendar

Last Earnings
11/04/2024
Today
9/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:IDXG
CIK
1054102
Employees
152
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$800 thousand
Net Margins
10.39%
Pretax Margin
10.93%
Return on Equity
-8.09%
Return on Assets
37.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.59
Quick Ratio
0.59

Sales & Book Value

Annual Sales
$40.21 million
Price / Sales
0.09
Cash Flow
$0.40 per share
Price / Cash Flow
1.99
Book Value
($14.16) per share
Price / Book
-0.06

Miscellaneous

Outstanding Shares
4,410,000
Free Float
4,167,000
Market Cap
$3.48 million
Optionable
Not Optionable
Beta
0.76
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:IDXG) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners